Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.

Khan, Sabrina S; Karn, Thomas; Symmans, W Fraser; Rody, Achim; Müller, Volkmar; Holtrich, Uwe; Becker, Sven; Pusztai, Lajos; Hatzis, Christos

Khan, Sabrina S; Karn, Thomas; Symmans, W Fraser; Rody, Achim; Müller, Volkmar; Holtrich, Uwe; Becker, Sven; Pusztai, Lajos; Hatzis, Christos.

Affiliation

Khan SS; Yale University School of Medicine, New Haven, CT, USA, sabrina.khan@yale.edu.

Breast Cancer Res Treat ; 149(3): 789-97, 2015 Feb.

Article in En | MEDLINE | ID: mdl-25651779

Subject(s)

Breast Neoplasms/drug therapy; Chemotherapy, Adjuvant; Gene Expression Profiling; Neoplasm Proteins/biosynthesis; Neoplasm Recurrence, Local/drug therapy; Adult; Antineoplastic Agents, Hormonal/administration & dosage; Biomarkers, Tumor/biosynthesis; Biomarkers, Tumor/genetics; Breast Neoplasms/genetics; Breast Neoplasms/pathology; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local/genetics; Neoplasm Recurrence, Local/pathology; Neoplasm Staging; Prognosis; Receptors, Estrogen/genetics; Tamoxifen/administration & dosage

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Chemotherapy, Adjuvant / Gene Expression Profiling / Neoplasm Proteins / Neoplasm Recurrence, Local Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2015 Type: Article

Fulltext

XML

PubMed Links

Search on Google